High DHODH levels correlate with poor clinical outcomes in colorectal cancer, hepatocellular carcinoma, glioblastoma, and triple-negative breast cancer [13,14,15,16,17]. This evidence concerns the gene DHODH and triple-negative breast carcinoma.